COVID-19 & Psoriasis Resource Center

To assist dermatologists and the patients they serve, the IPC is collecting information from around the world on coronavirus and psoriasis. If you have a resource on COVID-19 and psoriasis to add, please submit it to IPC.

Latest news on COVID-19 & Psoriasis

New data from the PsoProtect Registry

June 01, 2021

Expert Opinion: Psoriasis comprehensive review

May 25, 2021

Commentary: Sex differences in immune responses that underlie COVID-19 disease outcomes

May 17, 2021

Update on PsoProtect Registry Data

March 17, 2021

IPC Statement on COVID-19 & PsoriasisIPC's statement provides general guidance to physicians treating psoriasis patients based on the current understanding of the impact of COVID-19 and psoriasis.

Expert Opinions

Hear from world psoriasis experts their take on the most current publications on COVID-19.

Stories from the Field View videos and read interviews from some of IPC's experts regarding the impact on psoriasis care during the COVID-19 pandemic.

Treatment GuidelinesView recommendations from professional and patient societies around the globe that have provided additional information regarding treating patients with psoriasis during the COVID-19 pandemic.

PsoProtect Registry

Help us learn more about the impact on psoriasis and COVID-19 by participating in this global registry. You can submit a case on-line.

Key Publications Review articles on COVID-19 selected by IPC's Chief Medical Officer.

IPC STATEMENT
on SARS-CoV-2 Vaccines and Psoriasis

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.

READ FULL STATEMENT

The National Psoriasis Foundation
COVID-19 Task Force Guidance Statements

Twenty-five key recommendations for the management of patients with psoriatic disease during the COVID-19 pandemic.

READ STATEMENTS

THIS WEEKS' PUBLICATIONS ON COVID-19 & PSORIASIS

Psoriasis flare up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine
A 46-year-old Caucasian male presented with psoriasis flare up, which occurred a day after second dose of COVID-19 Pfizer-BioNTech BNT16B2b2 mRNA vaccine. The patient had been suffering from plaque psoriasis for 24 years. During the last 21 months his psoriasis was completely clear (PASI 0 points) due to deucravacitinib treatment in the clinical trial. Before entering the clinical trial two years ago the severity of his psoriasis was assessed as PASI 18 points. For the last 48 weeks he has been...

Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting
The coronavirus disease 2019 (COVID-19; caused by SARS-CoV-2) pandemic has affected the healthcare system on a global scale, and we utilized the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2020 annual meeting to examine how COVID-19 might affect patients with psoriatic disease (PsD) and the clinicians who care for them. Pressing issues and concerns identified included whether having psoriasis increased the risk of acquiring COVID-19, vaccine safety, and the...

Impact of Inflammatory Immune Dysfunction in Psoriasis Patients at Risk for COVID-19
Psoriasis is an immune-mediated dermatosis usually associated with comorbidities. Treatment varies from topicals to systemic drugs and data on susceptibility to viral infections in psoriatic patients are scarce. The objectives of this study were to analyze psoriatic patients on different therapies who were at risk for COVID-19 for seroprevalence of SARS-COV-2, pro-inflammatory cytokine profile, comorbidities and outcomes in order to unveil the immunological mechanisms involved in the anti-viral...

Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization and Mortality in Patients with Psoriasis: A Population-Based Study
CONCLUSIONS: The use of oral methotrexate was associated with an increased odds of COVID-associated hospitalization, whereas the use of biologic drugs was not associated with worse outcomes of COVID-19 among patients with psoriasis.

Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study
The risk of coronavirus disease 2019 (COVID-19) and its complications among patients with psoriasis treated by tumor necrosis factor inhibitors (TNFis) remains to be decisively delineated. We aimed to assess the risk of COVID-19 infection, COVID-19-associated hospitalization, and mortality among Israeli patients with psoriasis treated by TNFi relative to other systemic agents. A population-based cohort study was conducted to compare psoriasis patients treated by TNFi (n = 1943), with those...

VIEW ALL ON PUBMED

RECOURCES FROM OUR INDUSTRY PARTNERS

AbbVie
Amgen
Novartis
UCB